International
U.S Domestic
Available Domestic
Dragon Pharma
Dragon Pharma Livagen 20 mg KEDA Tetrapeptide Research Vial
Injection · 20 mg · vial
In stock · ships within 24h
Out of stock
$115.00
Dragon Pharma Livagen is the KEDA tetrapeptide, a short bioregulator supplied as a 20 mg lyophilized vial for research. It is positioned as a liver-focused peptide in the Russian short-peptide family, and the family format is a short block of one to three weeks.
GMP-manufactured and HPLC-verified, with a Certificate of Analysis on file. Livagen 20 mg for sale with U.S. domestic and international shipping.
Shipping
Not available in this combination
Discreet plain packaging
Worldwide reship guarantee
Crypto & card accepted
Product overview
Dragon Pharma Livagen 20 mg KEDA Peptide Vial
Dragon Pharma Livagen is a 20 mg lyophilized vial of the KEDA tetrapeptide, one of the short regulatory peptides developed in Russia around 2000. It is sold as a research bioregulator with a liver accent, and the vendor line places it beside Epitalon, GHK-Cu, KPV and the other short peptides of the same generation.
- 20 mg lyophilized powder in a single vial - research use
- Short regulatory tetrapeptide, sequence KEDA
- GMP-manufactured and HPLC-verified - COA on file per batch
- U.S. domestic and international shipping
How Livagen Works
The scientific background of the family is molecular rather than clinical: cell-level work links these peptides to histone proteins and to promoter accessibility, a mechanism studied in a dish and not a human outcome. For Livagen there are no randomised human studies and no established pharmacokinetic profile, and the liver targeting is a vendor description rather than a measured effect. No direct entry for Livagen was found in the WADA prohibited list, which is not the same as documented permission. The closest relative in the series is Ovagen.
Reconstitution & Storage
Add bacteriostatic water against the vial wall and swirl, without shaking. A 20 mg vial in 2 ml gives 10 mg/ml, where 1 mg is 0.1 ml or 10 units on a U-100 syringe; 1 ml gives 20 mg/ml, where 1 mg is 0.05 ml and a low-volume syringe helps. Vendor material mentions 0.5-2 mg per day, and the project family format is a block of one to three weeks repeated once or twice a year, where 1 mg per day covers 20 days. Store the powder at 2-8 C, away from light, and use a solution within about 28 to 30 days.
Quality & Authenticity
Every batch is produced under GMP conditions and checked by third-party HPLC, with a Certificate of Analysis held per batch. Keep the vial upright, protect it from light and avoid repeated freeze-thaw cycles. The family member with the testicular accent is on the Testagen page, and the pineal peptide of the same generation is on the Epitalon page.
For laboratory research only. Consult a healthcare professional before use.
Specifications
| Trade Name | Livagen |
| Generic Name | Short regulatory tetrapeptide, sequence KEDA |
| Manufacturer | Dragon Pharma |
| Dosage | 20 mg per vial |
| Package | 1 lyophilized vial |
| Drug Class | Research peptide, short bioregulator |
| Half-Life | Not established in humans |
| Verification | Third-party HPLC per batch, COA on file |
| Shipping | U.S. domestic and international |
Stacks
Research compounds only. Consult a healthcare professional before any use. Amounts shown are vendor and project-family practice, not clinical doses.
FAQ
Before you ask
Questions, answered
Livagen is the KEDA tetrapeptide, a short bioregulator with a liver accent in the vendor description. Laboratory interest in this peptide family is molecular: cell studies link the short peptides to histone proteins and to promoter accessibility, which is a mechanism, not a clinical outcome. There is no approved indication, no human trial program, and no pharmacokinetic profile for the peptide.
Add bacteriostatic water against the wall of the vial and swirl gently, without shaking the solution. With 2 ml of diluent a 20 mg vial gives 10 mg/ml, where 1 mg is 0.1 ml or 10 units on a U-100 syringe. With 1 ml it gives 20 mg/ml and 1 mg is only 0.05 ml, which needs a low-volume syringe for accuracy. Use the solution within about 28 to 30 days and keep it at 2-8 C.
The project family format is a short block of one to three weeks repeated once or twice a year, and vendor material mentions 0.5-2 mg per day. At 1 mg per day a 20 mg vial covers 20 days, so the arithmetic fits the family schedule. No human study establishes any of these numbers, and the block length is practice rather than a measured protocol.
The most described effect for this peptide family is local: pain, redness and itching at the injection site, managed by rotating sites and keeping the technique clean. An allergic reaction to the peptide is possible, so a small test amount first is reasonable. Beyond that there is no long-term safety data in humans, because the family has never been studied in randomised human trials.
No direct entry for Livagen was found in the WADA prohibited list in the fact sheet, and that finding is marked as not confirmed. The peptide is not a hormone and not an anabolic, so it does not fall into the obvious categories either. Anyone subject to testing should verify the current list rather than rely on this card.
Keep the lyophilized vial at 2-8 C, protected from light, and do not freeze the powder repeatedly. Once reconstituted, hold the solution at 2-8 C and use it within about 28 to 30 days. GenXXLGear ships Livagen 20 mg with U.S. domestic and international options, and each batch carries a Certificate of Analysis from third-party HPLC testing.
No reviews yet
Be the first to share your experience with Dragon Pharma Livagen 20 mg KEDA Tetrapeptide Research Vial
Log in to write a reviewComplete the cycle
Stack it with
International
International
Available Domestic
U.S Domestic
Available Domestic